

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

FORM 10-Q

QUARTERLY REPORT UNDER SECTION 13 OR 15(d)
--- OF THE SECURITIES EXCHANGE ACT OF 1934

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES ACT OF 1933

For Quarter Ended: February 28, 2009 Commission File Number 000-49908

CYTODYN, INC.

(Exact name of registrant as specified in its charter)

75-3056237

(I.R.S. Employer Identification No.)

COLORADO

State or other jurisdiction
of incorporation organization

1511 Third Street, Santa Fe, 87505

(Address of principal executive offices) (Zip code)

(Registrant's telephone number, including area code) (505) 988-5520

(Former address, changed sine last report)

Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No X
--- ---

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No
--- ---

Indicate by check mark whether the registrant is a large accelerated filer, and an accelerated filer, a non-accelerated filer, or a smaller reporting company. See Definition of "accelerated filer, large accelerated filer, and smaller reporting company" in 12(b)2 of the Exchange Act (check one)

Large Accelerated Filer --- Accelerated Filer ---

Non-accelerated Filer --- Smaller Reporting Company X ---

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): Yes No X
--- ---

On June 23, 2010, there were 19,890,796 shares outstanding of the registrant's no par common stock.

TABLE OF CONTENTS

	PAGE

PART I FINANCIAL INFORMATION	

Item 1 Financial Statements	

Condensed Consolidated Balance Sheets as of February 28, 2009 (unaudited) and May 31, 2008	1
Condensed Consolidated Statement of Operations for the Three and Nine months Ended February 28, 2009 and February 29, 2008, and for the Period from October 28, 2003	

	to February 28, 2009 (unaudited)	2
	Condensed Consolidated Statement of Changes in Stockholders' Deficit for the Period from October 28, 2003 to February 28, 2009 (unaudited)	3 - 6
	Condensed Consolidated Statement of Cash Flows for the Nine Months Ended February 28, 2009 and February 29, 2008 and for the Period from October 28, 2003 to February 28, 2009 (unaudited)	7 - 8
	Notes to Condensed Consolidated Financial Statements (unaudited)	9 - 23
Item 2	Management's Discussion and Analysis of Financial Condition and Results of Operations.	24
Item 3	Quantitative and Qualitative Disclosures About Market Risk	28
Item 4T	Controls and Procedures	28
PART II OTHER INFORMATION		
Item 1	Legal Proceedings	29
Item 2	Unregistered Sales of Equity Securities and Use of Proceeds	29
Item 3	Defaults Upon Senior Securities	29
Item 4	Submission of Matters to a Vote of Security Holders	29
Item 5	Other Information	29
Item 6	Exhibits	29

<TABLE>
<CAPTION>

PART I

Item 1. Financial Statements

Cytodyn, Inc.
(A Development Stage Company)
Condensed Consolidated Balance Sheet

	February 28, 2009 (unaudited)	May 31, 2008
<S>	<C>	<C>
Assets		
Current Assets:		
Cash	\$ 21,154	\$ 85,435
Prepaid insurance	136	43,978
Prepaid license fees	7,500	7,500
	-----	-----
Total current assets	28,790	136,913
Furniture and equipment, net	2,344	1,422
Intangible assets, net	282	647
Other Assets	31,475	37,240
	-----	-----
	\$ 62,891	\$ 176,222
	=====	=====
Liabilities and Shareholders' Deficit		
Current liabilities:		
Accounts payable	\$ 347,622	\$ 388,459
Accrued liabilities	24,424	25,274
Short-term portion of legal accrual	25,000	50,000
Accrued interest payable	69,850	44,337
	-----	-----
Total current liabilities	466,896	508,070
Long Term Liabilities		
Accrued salaries - related party	229,500	229,500
Notes payable	138,000	145,000
Convertible notes payable, net	20,927	20,927
Indebtedness to related parties	530,998	572,840
Legal accrual	--	25,000

Total Liabilities	1,386,321	1,501,337
Shareholders' deficit:		
Preferred stock, no par value; 5,000,000 shares authorized, 100,000 shares issued and outstanding	167,500	167,500
Common stock, no par value; 25,000,000 shares authorized, 14,999,807 and 12,546,407 shares issued and outstanding at February 28, 2009 and May 31, 2008, respectively	5,674,833	4,468,865
Additional paid-in capital	2,908,857	2,613,257
Accumulated deficit on unrelated dormant operations	(1,601,912)	(1,601,912)
Deficit accumulated during development stage	(8,472,708)	(6,972,825)
Total shareholders' deficit	(1,323,430)	(1,325,115)
	\$ 62,891	\$ 176,222

</TABLE>

See accompanying notes to condensed consolidated financial statements.

1

<TABLE>
<CAPTION>

Cytodyn, Inc.
(A Development Stage Company)
Condensed Consolidated Statements of Operations
(Unaudited)

	Three months ended,		Nine months ended,		October 28,
	2/28/2009	2/29/2008	2/28/2009	2/29/2008	through 2/28/2009
<S>	<C>	<C>	<C>	<C>	<C>
Operating expenses:					
General and administrative	\$ 245,671	\$ 142,037	\$ 906,154	\$ 583,064	\$ 5,431,703
Amortization / depreciation	2,376	416	7,017	1,418	181,013
Research and development	--	--	460,000	--	1,411,228
Legal fees	24,112	11,708	97,306	191,565	688,695
Commitments and contingencies	--	--	--	(150,000)	--
Total operating expenses	272,159	154,161	1,470,477	626,047	7,712,639
Operating loss	(272,159)	(154,161)	(1,470,477)	(626,047)	(7,712,639)
Interest income	--	--	--	--	1,627
Interest expense:					
Interest on convertible debt	--	(41,774)	--	(52,809)	(696,259)
Interest on notes payable	(10,986)	(24,172)	(29,406)	(25,978)	(65,437)
Loss before income taxes	(283,145)	(220,107)	(1,499,883)	(704,834)	(8,472,708)
Income tax provision	--	--	--	--	--
Net loss	\$ (283,145)	\$ (220,107)	\$ (1,499,883)	\$ (704,834)	\$ (8,472,708)
Basic and diluted loss per share	\$ (.02)	\$ (0.02)	\$ (.11)	(0.06)	\$ (.85)
Basic and diluted weighted average common shares outstanding	14,663,231	11,011,550	13,807,529	11,178,390	10,009,867

</TABLE>

See accompanying notes to condensed consolidated financial statements

2

<TABLE>
<CAPTION>

CytoDyn, Inc.
(A Development Stage Company)
Consolidated Statements of Changes in Shareholders' Deficit
Period October 28, 2003 through February 28, 2009

	Preferred Stock		Common Stock		Stock for	Additional	Accumulated	Deficit	Total
	Shares	Amount	Shares	Amount	Prepaid Services	Paid-in Capital	Deficit	Accumulated During Development Stage	
<S>	<C>	<C>	<C>	<C>	<C>	<C>	<C>	<C>	<C>
Balance at October 28, 2003, following recapitalization	--	\$ --	6,252,640	\$1,425,334	\$ --	\$ 23,502	\$ (1,594,042)	\$ --	\$ (145,206)

February through April 2004, sale of common stock less offering costs of \$54,000 (\$.30/share)	--	--	1,800,000	486,000	--	--	--	--	486,000
February 2004, shares issued to former officer as payment for working capital advance (\$.30/share)	--	--	16,667	5,000	--	--	--	--	5,000
Net loss at year ended May 31, 2004	--	--	--	--	--	--	(7,870)	(338,044)	(345,914)
Balance at May 31, 2004	--	--	8,069,307	1,916,334	--	23,502	(1,601,912)	(338,044)	(120)
July 2004, capital contribution by an officer	--	--	--	--	--	512	--	--	512
November 2004, common stock warrants granted	--	--	--	--	--	11,928	--	--	11,928
February 2005, capital contribution by an officer	--	--	--	--	--	5,000	--	--	5,000
Net loss at year ended May 31, 2005	--	--	--	--	--	--	--	(777,083)	(777,083)
Balance at May 31, 2005	--	--	8,069,307	1,916,334	--	40,942	(1,601,912)	(1,115,127)	(759,763)

See accompanying notes to condensed consolidated financial statements

3

CytoDyn, Inc.
(A Development Stage Company)
Consolidated Statements of Changes in Shareholders' Deficit
Period October 28, 2003 through February 28, 2009

	Preferred Stock		Common Stock		Stock for Prepaid Services	Additional Paid-in Capital	Accumulated Deficit	Deficit Accumulated During Development Stage	Total
	Shares	Amount	Shares	Amount					
June through July 2005, sale of common stock less offering costs of \$27,867 (\$.75/share)	--	--	289,890	189,550	--	--	--	--	189,550
August 2005, common shares issued to extinguish promissory notes payable and related interest (\$.75/share)	--	--	160,110	120,082	--	--	--	--	120,082
May 2006, common shares issued to extinguish convertible debt	--	--	350,000	437,500	--	--	--	--	437,500
November 2005, 94,500 warrants exercised (\$.30/share)	--	--	94,500	28,350	--	--	--	--	28,350
January through April 2006, common shares issued for prepaid services	--	--	183,857	370,750	(370,750)	--	--	--	--
Amortization of prepaid stock services	--	--	--	--	103,690	--	--	--	103,690
January through June 2006, warrants issued with convertible debt	--	--	--	--	--	274,950	--	--	274,950
January through May 2006, beneficial conversion feature of convertible debt	--	--	--	--	--	234,550	--	--	234,550
March through May 2006, stock options granted to consultants	--	--	--	--	--	687,726	--	--	687,726
March 2006, stock options issued to extinguish debt	--	--	--	--	--	86,341	--	--	86,341

Net loss at year ended May 31, 2006	--	--	--	--	--	--	--	(2,053,944)	(2,053,944)
Balance at May 31, 2006	--	--	9,147,664	3,062,566	(267,060)	1,324,509	(1,601,912)	(3,169,071)	(650,968)

See accompanying notes to condensed consolidated financial statements

4

CytoDyn, Inc.
(A Development Stage Company)
Consolidated Statements of Changes in Shareholders' Deficit
Period October 28, 2003 through February 28, 2009

	Preferred Stock		Common Stock		Stock for Prepaid Services	Additional Paid-in Capital	Accumulated Deficit	Deficit Accumulated During Development Stage	Total
	Shares	Amount	Shares	Amount					
Common stock issued to extinguish convertible debt	--	--	119,600	149,500	--	--	--	--	149,500
Convertible debt stock issued for AITI acquisition	--	--	2,000,000	934,399	--	--	--	--	934,399
Amortization of prepaid stock services	--	--	--	--	267,060	--	--	--	267,060
Common stock payable for prepaid services	--	--	--	--	(106,521)	120,000	--	--	13,479
Stock-based compensation	--	--	--	--	--	535,984	--	--	535,984
Warrants issued with convertible debt	--	--	--	--	--	92,500	--	--	92,500
Common stock issued for services	--	--	30,000	26,400	--	--	--	--	26,400
Preferred shares issued AGTI	100,000	167,500	--	--	--	--	--	--	167,500
Net loss, May 31, 2007	--	--	--	--	--	--	--	(2,610,070)	(2,610,070)
Balance at May 31, 2007	100,000	167,500	11,297,264	4,172,865	(106,521)	2,072,993	(1,601,912)	(5,779,141)	(1,074,216)
Amortization of prepaid stock for services	--	--	--	--	106,521	--	--	--	106,521
Stock based compensation	--	--	--	--	--	461,602	--	--	461,602
Common stock issued to extinguish convertible debt	--	--	750,000	75,000	--	--	--	--	75,000
Rescission of common stock issued for services	--	--	(142,857)	(100,000)	--	--	--	--	(100,000)

See accompanying notes to condensed consolidated financial statements

5

CytoDyn, Inc.
(A Development Stage Company)
Consolidated Statements of Changes in Shareholders' Deficit
Period October 28, 2003 through February 28, 2009

	Preferred Stock		Common Stock		Stock for Prepaid Services	Additional Paid-in Capital	Accumulated Deficit	Deficit Accumulated During Development Stage	Total
	Shares	Amount	Shares	Amount					
Original issue discount convertible debt with warrants	--	--	--	--	--	3,662	--	--	3,662
Original issue discount convertible debt with beneficial conversion feature	--	--	--	--	--	75,000	--	--	75,000
Stock issued for cash (\$.50/share)	--	--	642,000	321,000	--	--	--	--	321,000
Net loss	--	--	--	--	--	--	--	(1,193,684)	(1,193,684)

Balance at May 31, 2008	100,000	\$167,500	12,546,407	\$4,468,865	\$ --	\$2,613,257	\$(1,601,912)	\$(6,972,825)	\$(1,325,115)
Stock issued for cash, \$.50/share (unaudited)	--	--	1,801,800	900,900	--	--	--	--	900,900
Stock issued for services \$.50/share (unaudited)	--	--	388,200	194,100	--	--	--	--	194,100
Stock issued for services \$.37/share (unaudited)	--	--	150,000	55,500	--	--	--	--	55,500
Stock-based compensation (unaudited)	--	--	--	--	--	288,700	--	--	288,700
Stock issued in payment of accounts payable, \$.50/share (unaudited)	--	--	98,000	49,000	--	--	--	--	49,000
Stock issued for services \$.42/share (unaudited)	--	--	15,400	6,468	--	--	--	--	6,468
Capital contribution (unaudited)	--	--	--	--	--	6,900	--	--	6,900
Net loss, ended February 28, 2009 (unaudited)	--	--	--	--	--	--	--	(1,499,883)	(1,499,883)
	100,000	\$167,500	14,999,807	\$5,674,833	--	\$2,908,857	\$(1,601,912)	\$(8,472,708)	\$(1,323,430)

</TABLE>

See accompanying notes to condensed consolidated financial statements

6

<TABLE>

<CAPTION>

CytoDyn, Inc.
(A Development Stage Company)
Consolidated Statements of Cash Flows
(Unaudited)

	Nine months ended		October 28,
	2/28/2009	2/29/2008	2003 through 2/28/2009
<S>	<C>	<C>	<C>
Cash flows from operating activities			
Net loss	\$(1,499,883)	\$ (704,834)	(8,472,708)
Adjustments to reconcile net loss to net cash used by operating activities:			
Amortization / depreciation	1,394	1,419	175,390
Amortization of original issue discount	--	50,972	677,588
Reversal of contingent liability	--	(150,000)	--
Purchased in process research and development	--	--	274,399
Stock-based compensation	544,768	346,130	2,710,443
Changes in current assets and liabilities:			
Accrued legal settlement	(50,000)	--	25,000
Prepaid expenses	43,842	74,578	(7,636)
Other assets	5,765	--	(31,475)
Accounts payable, accrued interest and accrued liabilities	32,826	193,311	720,396
Deposits	--	(38,880)	--
Net cash used in operating activities	(921,288)	(227,304)	(3,928,603)
Cash flows from investing activities:			
Furniture and equipment purchases	(1,951)	--	(12,715)
Net cash used in investing activities	(1,951)	--	(12,715)
Cash flows from financing activities:			
Capital contributions by president	6,900	--	12,412
Proceeds from notes payable to related parties	--	2,000	702,649
Payments on notes payable to related parties	(41,842)	(20,300)	(117,827)
Proceeds from notes payable issued to individuals	--	170,000	145,000
Payments on notes payable issued to individuals	(7,000)	--	(7,000)
Proceeds from convertible notes payable	--	59,000	686,000
Proceeds from the sale of common stock	900,900	--	1,979,317
Payments for offering costs	--	--	(81,867)
Proceeds from issuance of stock of AITI acquisition	--	--	512,200
Proceeds from issuance of stock of AGTI acquisition	--	--	100,000
Proceeds from exercise of warrants	--	--	28,350
Net cash provided by financing activities	858,958	210,700	3,959,234
Net change in cash	(64,281)	(16,604)	17,916
Cash, beginning of period	85,435	16,604	3,238
Cash, end of period	\$ 21,154	\$ --	21,154

Supplemental disclosure of cash flow information:			
Cash paid during the period for:			
Income taxes	\$ --	\$ --	--
Interest	\$ --	\$ --	3,036

7

CytoDyn, Inc.
(A Development Stage Company)
Consolidated Statements of Cash Flows
(Unaudited)

	Nine months ended		October 28, 2003
	2/28/2009	2/29/2008	through 2/28/2009
Non-cash investing and financing transactions:			
Net assets acquired in exchange for common stock in CytoDyn/Rexray business combination	--	--	7,542
Common stock issued to former officer to repay working capital advance	--	--	5,000
Common stock issued for convertible debt	--	75,000	662,000
Common stock issued for debt	--	--	120,082
Common stock issued on payment of accounts payable	49,000	--	49,000
Options to purchase common stock issued for debt	--	--	62,341
Original issue discount and intrinsic value of beneficial conversion feature related to debt issued with warrants	--	53,662	680,662

</TABLE>

See accompanying notes to condensed consolidated financial statements

8

CYTODYN, INC.
(A DEVELOPMENT STAGE COMPANY)
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
AS OF February 28, 2009
(UNAUDITED)

1 - Organization:

CytoDyn, Inc. (the "Company") was incorporated under the laws of Colorado on May 2, 2002 under the name Rexray Corporation ("Rexray"). In October 2003 we entered into an Acquisition Agreement with CytoDyn of New Mexico, Inc., pursuant to which we effected a one for two reverse split of our common stock, and amended our articles of incorporation to change our name from Rexray Corporation to CytoDyn, Inc. The acquisition was accounted for as a reverse merger and recapitalization of the Company. Pursuant to the acquisition agreement, we were assigned the patent license agreement dated July 1, 1994 between CytoDyn of New Mexico and Allen D. Allen covering three United States patents along with foreign counterpart patents which describe a method for treating HIV disease with the use of monoclonal antibodies. We also acquired the trademarks, CytoDyn and Cytolin, and a related trademark symbol. The license acquired gives us the worldwide, exclusive right to develop, market, sell and profit from the HIV therapies from the patents, technology and know-how invented by Mr. Allen. The term of the license agreement is for the life of the patents. The original expiration dates on the issued patents are 2013 to 2016. There is an automatic extension of the expiration date on U.S. patents equal to the number of years the drug under the patent is being studied in clinical trials. Typically this provides another four to five years on the earliest claims. CytoDyn's counsel expects its patents to be extended until 2017 to 2020 depending upon the original date of the issued patents. As consideration for the intellectual property and trademarks we paid CytoDyn of New Mexico \$10,000 in cash and issued 5,362,640 post-split shares of common stock to CytoDyn of New Mexico.

The Company entered the development stage effective October 28, 2003 upon the reverse merger and recapitalization of the Company and follows Financial Standard Accounting Codification No. 915, Development Stage Entities.

CytoDyn, Inc. discovered and is developing a class of therapeutic monoclonal antibodies to address significant unmet medical needs in the areas of HIV and AIDS.

CYTODYN, INC.
 (A DEVELOPMENT STAGE COMPANY)
 NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
 AS OF February 28, 2009
 (UNAUDITED)

2 - Summary of Significant Accounting Policies:

Basis of Presentation

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) and reflect all adjustments, consisting solely of normal recurring adjustments, needed to fairly present the financial results for these periods. The condensed consolidated financial statements and notes are presented as permitted by Form 10-Q. Accordingly, certain information and note disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted. The accompanying consolidated financial statements should be read in conjunction with the financial statements for the years ended May 31, 2008 and 2007 and notes thereto in the Company's annual report on Form 10-K for the year ended May 31, 2008, filed with the Securities and Exchange Commission on March 12, 2010. Operating results for the three and nine months ended February 28, 2009 and February 29, 2008 are not necessarily indicative of the results that may be expected for the entire year. In the opinion of management, all adjustments consisting only of normal recurring adjustments necessary for a fair statement of (a) the results of operations for the three and nine month periods ended February 28, 2009 and February 29, 2008 and the period October 28, 2003 through February 28, 2009, (b) the financial position at February 28, 2009, and (c) cash flows for the nine month periods ended February 28, 2009 and February 29, 2008 and the period October 28, 2003 through February 28, 2009, have been made.

Principles of Consolidation

The consolidated financial statements include the accounts of CytoDyn, Inc. and its wholly owned subsidiaries; AITI and AIGI All intercompany transactions and balances are eliminated in consolidation.

Going Concern

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the accompanying consolidated financial statements, the Company is currently in the development stage with losses for all periods presented. As of June 23, 2010 these factors, among others, raise substantial doubt about the Company's ability to continue as a going concern.

The consolidated financial statements do not include any adjustments relating to the recoverability of assets and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company's continuation as a going concern is dependent upon its ability to obtain additional operating capital,

CYTODYN, INC.
 (A DEVELOPMENT STAGE COMPANY)
 NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
 AS OF February 28, 2009
 (UNAUDITED)

complete development of its medical treatment, obtain FDA approval, outsource manufacturing of the treatment, and ultimately to attain profitability. The Company intends to seek additional funding through equity offerings to fund its business plan. There is no assurance that the Company will be successful in these endeavors.

Use of Estimates

The preparation of the consolidated financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Cash and Cash Equivalents

The Company considers all highly liquid debt instruments with original maturities of three months or less when acquired to be cash equivalents. The Company had no cash equivalents as of February 28, 2009 or May 31, 2008. The Company maintains its cash in bank deposit accounts, which at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts.

Furniture, Equipment and Depreciation

Furniture and equipment are stated at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the related assets, generally three to seven years. Maintenance and repairs are charged to expense as incurred and major improvements or betterments are capitalized. Gains or losses on sales or retirements are included in the consolidated statements of

operations in the year of disposition.

Impairment of Long-Lived Assets

The Company evaluates the carrying value of any long-lived assets under U.S. GAAP, which requires impairment losses to be recorded on long-lived assets used in operations when indicators of impairment are present and the undiscounted future cash flows estimated to be generated by those assets are less than the assets' carrying amount. If such assets are impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying value or fair value, less costs to sell. There were no impairment charges for the three and nine months ended February 28, 2009 and February 29, 2008, and for the period October 28, 2003 through February 28, 2009.

Research and Development

Research and development costs are expensed as incurred.

11

CYTODYN, INC.
(A DEVELOPMENT STAGE COMPANY)
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
AS OF February 28, 2009
(UNAUDITED)

Financial Instruments

At February 28, 2009 and May 31, 2008, the carrying value of the Company's financial instruments approximate fair value due to the short-term maturity of the instruments. The Company's notes payable have market rates of interest, and accordingly, the carrying values of the notes approximates the fair value.

Stock-Based Compensation

U.S GAAP requires companies to measure the cost of employee services received in exchange for the award of equity instruments based on the fair value of the award at the date of grant. The expense is to be recognized over the period during which an employee is required to provide services in exchange for the award (requisite service period). U.S. GAAP provides for two transition methods. The "modified prospective" method requires that share-based compensation expense be recorded for any employee options granted after the adoption date and for the unvested portion of any employee options outstanding as of the adoption date. The "modified retrospective" method requires that, beginning upon adoption, all prior periods presented be restated to reflect the impact of share-based compensation expense consistent with the pro forma disclosures previously required under U.S. GAAP. The Company adopted the modified prospective method, and as a result, was not required to restate its financial results for prior periods. The Company accounts for common stock options, and common stock warrants granted based on the fair market value of the instrument using the Black-Scholes option pricing model utilizing certain weighted average assumptions such as expected stock price volatility, term of the options and warrants, risk-free interest rates, and expected dividend yield at the grant date. The risk-free interest rate assumption is based upon observed interest rates appropriate for the expected term of the stock options. The expected volatility is based on the historical volatility of the Company's common stock at consistent intervals. The Company has not paid any dividends on its common stock since its inception and does not anticipate paying dividends on its common stock in the foreseeable future. The computation of the expected option term is based on the "simplified method" as the Company's stock options are "plain vanilla" options and the Company has a limited history of exercise data. For common stock options and warrants with graded vesting, the Company recognizes the related compensation costs associated with these options and warrants on the straight-line basis over the requisite service period.

U.S GAAP requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Based on limited historical experience of forfeitures, the Company estimated future unvested option forfeitures at 0% as of February 28, 2009 and February 29, 2008.

12

CYTODYN, INC.
(A DEVELOPMENT STAGE COMPANY)
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
AS OF February 28, 2009
(UNAUDITED)

Stock for Services

The Company issues common stock and common stock options to consultants for various services. Costs for these transactions are measured at the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. The value of the common stock is measured at the earlier of (i) the date at which a firm commitment for performance by the counterparty to earn the equity instruments is reached or (ii) the date at which the counterparty's performance is complete.

Earnings (Loss) per Common Share

Basic earnings (loss) per share is computed by dividing the net income or loss by the weighted average number of common shares outstanding during the period.

Diluted earnings (loss) per share is computed by dividing net income (loss) by the weighted average common shares and potentially dilutive common share equivalents. The effects of potential common stock equivalents are not included in computations when their effect is antidilutive. Because of the net loss for the three and nine month periods ended February 28, 2009 and February 29, 2008, the basic and diluted weighted average shares outstanding are the same since including the additional shares would have an antidilutive effect on the loss per share calculation. Common stock option and warrants to purchase 3,326,222 and 2,906,222 shares of common stock were not included in the computation of basic and diluted weighted average common shares outstanding for the three and nine months ended February 28, 2009 and February 29, 2008, respectively. Additionally, subsequent to February 28, 2009, the Company has issued common stock, and potentially dilutive warrants and options (See Note 10).

Reclassification

Certain prior period amounts have been reclassified to comply with current period presentation.

3 - Recent Accounting Pronouncements:

In June 2009, the FASB issued ASC 105 Accounting Standards Codification TM and the Hierarchy of Generally Accepted Accounting Principles. The FASB Accounting Standards Codification TM (the "Codification") has become the source of authoritative accounting principles recognized by the FASB to be applied by nongovernmental entities in the preparation of financial statements in accordance with Generally Accepted Accounting Principles ("GAAP"). All existing accounting standard documents are superseded by the Codification and any accounting literature not included in the Codification will not be authoritative. Rules and interpretive releases of the SEC issued

13

CYTODYN, INC.
(A DEVELOPMENT STAGE COMPANY)
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
AS OF February 28, 2009
(UNAUDITED)

under the authority of federal securities laws, however, will continue to be the source of authoritative generally accepted accounting principles for SEC registrants. Effective September 30, 2009, all references made to GAAP in our consolidated financial statements will include references to the new Codification. The Codification does not change or alter existing GAAP and, therefore, will not have an impact on our financial position, results of operations, or cash flows.

In June 2009, the FASB issued changes to the consolidation guidance applicable to a variable interest entity (VIE). FASB ASC Topic 810, "Consolidation," amends the guidance governing the determination of whether an enterprise is the primary beneficiary of a VIE and is, therefore, required to consolidate an entity by requiring a qualitative analysis rather than a quantitative analysis. The qualitative analysis will include, among other things, consideration of who has the power to direct the activities of the entity that most significantly impact the entity's economic performance and who has the obligation to absorb losses or the right to receive benefits of the VIE that could potentially be significant to the VIE. This standard also requires continuous reassessments of whether an enterprise is the primary beneficiary of a VIE. FASB ASC 810 also requires enhanced disclosures about an enterprises' involvement with a VIE. Topic 810 is effective as of the beginning of interim and annual reporting periods that begin after November 15, 2009. This will not have an impact on the Company's financial position, results of operations, or cash flows.

In June 2009, the FASB issued Financial Accounting Standards Codification No. 860, "Transfers and Servicing." FASB ASC No. 860 improves the relevance, representational faithfulness, and comparability of the information that a reporting entity provides in its financial statements about a transfer of financial assets; the effects of a transfer on its financial position, financial performance, and cash flows; and a transferor's continuing involvement, if any, in transferred financial assets. FASB ASC No. 860 is effective as of the beginning of each reporting entity's first annual reporting period that begins after November 15, 2009, for interim periods within the first annual reporting period, and for the interim and annual reporting periods thereafter. This will not have an impact on the Company's financial position, results of operations, or cash flows.

Other recent accounting pronouncements issued by the FASB (including its EITF), the AICPA, and the SEC did not or are not believed by management to have a material impact on the Company's present or future consolidated financial statements.

4 - Acquisitions:

On July 18, 2006, CytoDyn, Inc. entered into an acquisition agreement with UTEK Corporation to purchase all 1,000 issued and outstanding shares of Advanced Influenza Technologies, Inc. (AITI), a Florida Corporation, in exchange for 2,000,000 unregistered restricted common shares of CytoDyn, Inc. stock.

14

(A DEVELOPMENT STAGE COMPANY)
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
AS OF February 28, 2009
(UNAUDITED)

The transaction was accounted for as an asset purchase and not an acquisition of a business as AITI had no employees, operations, or customers, and was essentially a shell corporation that was incorporated to consummate the purchase. Pursuant to the agreement, the Company acquired \$512,200 in cash and a prepaid sponsored research project of \$162,800 from the University of Massachusetts to further the technology associated with certain acquired licenses. The \$162,800 is being amortized into research and development expense as the services are provided. The Company valued the assets acquired based on the consideration received rather than the fair market value of the shares issued as the Company believes this was more indicative of the value of the assets acquired. In addition to the cash and the prepaid sponsored research project, the Company acquired the worldwide nonexclusive and exclusive license agreements from the University of Massachusetts for certain technologies. The license agreements were recorded as research and development expense as the patent rights or license agreements are being used in a particular research project and have no alternative future use outside of this project. The license agreement grants the Company the exclusive right to develop and commercialize the licensed products associated with certain existing patents.

Milestone fees are payable to the University per licensed product and due within 30 days of the event of certain occurrences required.

The University shall also receive 4.0% royalties on net sales of the licensed products.

AITI agreed to fund a two-year (\$325,600) unrestricted project (\$162,800 per year) under the Sponsored Research Agreement, with the primary objective during the first year to conduct lab work to provide well documented research studies. If after one year the desired outcome is not achieved, the agreement can be cancelled and the second year's payment is not required. The Company did not make the second payment and, consequently, the Company has no right to the above license agreement. Additionally, the milestone fee payable and royalties discussed above are no longer in force.

On January 30, 2007, CytoDyn, Inc. entered into an acquisition agreement with UTEK Corporation, to acquire 100% of the outstanding stock of Advanced Genetic Technologies, Inc. (AGTI), a Florida Corporation, in exchange for 100,000 preferred no par value stock convertible into \$1,300,000 worth of common unregistered restricted

15

CYTODYN, INC.
(A DEVELOPMENT STAGE COMPANY)
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
AS OF February 28, 2009
(UNAUDITED)

shares of CytoDyn, Inc. stock. The option to convert is any time after twelve (12) months and before thirty six (36) months from the date of closing of the agreement. The conversion option has a floor price of \$.30 per share, which limits the maximum number of shares that the Company may issue upon conversion to 4,333,333 shares of common stock (see Note 10). There was no derivative liability or beneficial conversion feature associated with the conversion option.

AGTI holds the worldwide exclusive and nonexclusive license agreements from the CBR Institute for Biomedical Research affiliated with Harvard Medical School for certain biological materials.

The term of the licensing agreement is until the later of 20 years or the date the last patent expires that is owned or controlled by the Licensee.

Milestone fees are payable to the University per licensed product and due within 30 days of the event of certain occurrences required.

The University shall also receive 2.0% royalties of net sales of the licensed products up to \$200 million and 3.0% royalties of net sales in excess of \$200 million. In the case of a sublicense, the University would get 25% of non-royalty sublicense income.

The transaction was accounted for as an asset purchase and not an acquisition of a business as AGTI had no employees, operations, or customers, and was essentially a shell corporation that was incorporated to consummate the purchase. Pursuant to the agreement, the Company acquired \$100,000 in cash and seven years of prepaid license fees to the Center for Biological Research at Harvard Medical School. \$52,500 was recorded as prepaid license fees and \$15,000 was expensed as research and development. The Company valued the assets acquired based on the consideration received rather than the fair market value of the shares issued as the Company believes this was more indicative of the value of the assets acquired. In addition to the cash and the prepaid license fees, the Company acquired the worldwide nonexclusive and exclusive license agreements from the Center for Biological Research at Harvard Medical School for certain biological materials. The license agreement grants the Company the exclusive right to develop and commercialize the licensed products associated with certain biological materials.

CYTODYN, INC.
(A DEVELOPMENT STAGE COMPANY)
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
AS OF February 28, 2009
(UNAUDITED)

5 - Convertible Notes:

During the year ended May 31, 2007, the Company issued convertible notes with 74,000 detachable common stock warrants to purchase common stock in exchange for proceeds of \$92,500. The notes bear interest at 5.0% per annum. Principal and accrued interest are payable in any combination of cash and common stock at the option of the Company. The Company can repay principal and accrued interest with common stock at the conversion price of \$1.25. As of November 30, 2008, \$77,500 of the \$92,500 in convertible notes were converted into common stock. The warrants to purchase common stock which accompanied the convertible promissory notes are exercisable at \$2.50 per share, vest immediately, and expire in October 2010. Additionally, the Company recorded an original issue discount based on the fair value of the warrants. To recognize the original issue discount, the Company discounted the notes and increased additional paid-in capital by \$92,500. The Company did not record the intrinsic value for conversion into the Company's common stock, as the discount was limited to the debt proceeds of \$92,500, which was fully discounted by the fair value of the warrants. The discount was amortized over the life of the debt. During the three and nine month periods ended February 28, 2009 and 2008, the Company amortized approximately \$0 and \$615 of this discount, respectively, which is included as a component of interest expense. From October 28, 2003 to February 28, 2009, the Company amortized \$92,500 of discounts related to convertible notes payable.

CYTODYN, INC.
(A DEVELOPMENT STAGE COMPANY)
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
AS OF February 28, 2009
(UNAUDITED)

During the year ended May 31, 2008, the Company issued a convertible promissory note with 9,000 detachable warrants to purchase common stock at an exercise price of \$.30 in exchange for proceeds totaling \$9,000. The note bears interest at 14.0%. The warrants to purchase common stock vest immediately and expire in 2011. The Company valued the warrants utilizing the Black-Scholes option valuation model, and the resulting fair value was recorded as a debt discount of \$3,662.

6 - Promissory Notes:

During the year ended May 31, 2007, the Company issued \$125,000 in unsecured promissory notes to third parties. The principal and interest on the notes were originally due in six months and pay interest at 14.0% per annum. During the year ended May 31, 2008, the Company issued an additional \$20,000 in promissory notes to third parties. The balance of the promissory notes was \$138,000 as of February 28, 2009. The notes were all due in six months and pay interest of 14.0% per annum. The parties have agreed to extend the due date in six months increments while continuing to accrue interest. Additionally, subsequent to July 2009, the notes were amended to become convertible into common stock (see Note 10). As a result of the extension of terms, and the conversion of some of the promissory notes to common stock, the Company has classified all of the notes as long-term as of February 28, 2009.

7 - Equity:

The Company has one stock-based equity plan at November 30, 2008. The 2005 Stock Incentive Plan as amended (the "Plan") was authorized to issue options and warrants to purchase up to 2,800,000 shares of the Company's common stock. As of February 28, 2009 the company had 448,878 shares available for future stock option grants under the plan.

The estimated fair value of options and warrants is determined using the Black-Scholes option valuation model with the following weighted-average assumption for the nine month periods ended February 28, 2009 and February 29, 2008:

	2009	2008
	-----	-----
Risk free rate	2.56% - 2.84%	3.00%
Dividend Yield	0.00	0.00
Volatility	124.00% - 156.00%	71.00%
Expected term	3.00 years	5.50 years

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
AS OF February 28, 2009
(UNAUDITED)

Net cash proceeds from the exercise of stock options and warrants were \$0 for the nine months ending February 28, 2009 and February 29, 2008, respectively. Compensation expense related to stock options and warrants was approximately \$83,000, and \$105,000 for the three months ended February 28, 2009 and February 29, 2008, respectively, and \$289,000 and \$356,000 for the nine months ended February 28, 2009 and February 29, 2008, respectively. During the nine months ended February 28, 2009 the company granted 205,000 options to employees and directors, which were valued and recorded as compensation expense.

The grant date fair value of options vested during the nine month periods ended February 28, 2009 and February 29, 2008 was approximately \$279,000 and \$225,000, respectively. The weighted average grant date fair value of options and warrants granted during the nine month period ended February 28, 2009 and February 29, 2008 was \$.30 and \$.42, respectively. As of February 28, 2009 there was approximately \$384,000 of unrecognized compensation costs related to share-based payments for unvested options, which is expected to be recognized over a weighted average period of 1.17 years.

The following table represents stock option and warrant activity as of and for the nine months ended February 28, 2009:

	Number of Shares	Weighted Average Exercise Price	Weighted Average Remaining Contractual Life	Aggregate Intrinsic Value
	-----	-----	-----	-----
Options and warrants				
outstanding - May 31, 2008	3,227,222	\$1.30	6.52	\$ 143,000
Granted	205,000	\$0.34		
Exercised	0			
Forfeited/expired/cancelled	(106,000)	\$0.30		
Options and warrants				
outstanding - February 28, 2009	3,326,222	\$1.27	6.02	\$ 29,180
Outstanding exercisable				
- February 28, 2009	2,895,074	\$1.33	5.80	\$ 27,108

During the year ended May 31, 2006, the Company issued 142,857 restricted shares to a public relations company in accordance with an agreement to perform services over the following year. The Company valued the shares at the market price of the Company's common stock on the date the agreement was executed in the amount of \$250,000. On July 16, 2007, the Company cancelled the 142,857 shares of restricted common stock for non-performance. The expense associated with the original issuance had previously been amortized as compensation expense over the requisite life of the agreement. In conjunction with the cancellation, the Company reduced compensation expense by \$100,000 at the date of cancellation for non-performance under the contract, which represented the fair market value of the common stock on the date of cancellation.

19

CYTODYN, INC.
(A DEVELOPMENT STAGE COMPANY)
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
AS OF February 28, 2009
(UNAUDITED)

During the year ended May 31, 2007, the Company issued 40,000 restricted common shares to a consulting company in accordance with an agreement to perform services over the following year. The Company valued the shares at the market price of the Company's common stock on the date the agreement was executed in the amount of \$120,000. For the three and nine-month periods ended February 29, 2008, the Company recognized approximately \$30,000 and \$90,000 of compensation expense related to this agreement. There was no compensation expense recognized in the corresponding comparable periods.

During the nine month period ended February 28, 2009, the Company issued 503,600 restricted shares of common stock for past consulting services. The Company recorded approximately \$256,000 in consulting expense during the nine month period ended February 28, 2009 related to this transaction. The Company valued the shares issued based on third-party sales of common stock issued during the same period, which approximated the fair value of the common stock at the respective commitment dates.

8 - Commitments and Contingencies:

In 2001, the Company sued its previous licensee, Amerimmune Pharmaceuticals, Inc. ("API") and its directors. The Company was ordered by the court to pay \$150,000 in attorney fees to the insurance company of API and recorded a contingent liability for the amount. The Company appealed the Court's decision and, in December 2007, the Court's decision was reversed based on the appeal. Based on these facts and circumstances, the Company reversed the contingent liability during 2007.

Related to certain litigation whereby the Company was both a defendant and a

plaintiff, the Company entered into a settlement agreement in December 2008. As part of the settlement agreement, the Company agreed to pay \$50,000 in January 2009 and \$25,000 on or before January 14, 2010 to the plaintiff. The Company paid the \$50,000 in January 2009. The remaining \$25,000 was unsecured and accrued interest at 10.0 percent per annum. The Company paid \$27,500 in January 2010. As of February 28, 2009, the Company has an accrual of \$25,000 related to this settlement Agreement.

9 - Related Party Transactions:

As of February 28, 2009, the Company owed an officer promissory notes totaling of \$2,672. The notes are due on demand and carry no interest rate. Management plans to repay the notes through cash payments, issuance of the Company's common stock, or a combination thereof. The balance due is included in the accompanying consolidated financial statements as "indebtedness to related parties" and is treated as long-term as the amounts were not paid by February 28, 2010.

20

CYTODYN, INC.
(A DEVELOPMENT STAGE COMPANY)
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
AS OF February 28, 2009
(UNAUDITED)

A director provided legal services to the Company over the past several years. As of February 28, 2009, the Company owed the director \$40,985 and it is included in the accompanying consolidated financial statements as "indebtedness to related parties" as of February 28, 2009. As of February 28, 2009 no arrangements had been made for the Company to repay the balance of this obligation. The Company anticipates that the director will continue to provide legal services in the future. Since this has not been paid as of June 23, 2010, it is treated as long-term in the accompanying financial statements.

A former director of the Company is owed \$337,341 related to certain clinical research data that was obtained by the former director and later purchased by the Company. As of February 28, 2009 the liability has no payment terms and no stated interest rate, and is included in the accompanying consolidated financial statements as "indebtedness to related parties." Since this has not been paid as of June 23, 2010, it is treated as long-term in the accompanying financial statements.

In May and July 2007, the Company issued \$150,000 in promissory notes with a stated interest rate of 14%, and a maturity date of six months from the issuance date. The notes were originally issued to an unrelated third, who subsequently became director of the company during 2008. Accordingly, the notes are classified as related party notes as of February 28, 2009 and have been designated as long-term as the notes have been extended multiple times and have no stated maturity date and has not been repaid as of June 23, 2010.

10 - Subsequent Events:

In April 2008, the Company's Board of Directors approved a Private Placement Memorandum to sell up to 6 million shares of common stock, no par value, a company offering. This offering was only available to accredited investors as defined under the 1933 Securities Act ("The Act"). The offering commenced on or about May 1, 2008 and ended June 15, 2009, the Company has sold 3,876,508 restricted common shares and 1,938,254 warrants for proceeds totaling approximately \$2,000,000. These securities were sold pursuant to an exemption from registration under Regulation D under The Act and will not be registered with the Securities and Exchange Commission. The warrants have an exercise price of \$1.00 per share, immediate vesting rights, and expire in April 2013.

21

CYTODYN, INC.
(A DEVELOPMENT STAGE COMPANY)
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
AS OF February 28, 2009
(UNAUDITED)

In July 2009, the Company amended certain promissory note agreements relating to unsecured related party promissory notes. The original terms had no conversion feature, a stated interest rate of 14% per annum, and had an original maturity of six months. Related to this amendment, the holders of the promissory notes were given the right to convert the face amount of the notes and accrued interest into shares of common stock at a fixed conversion price of \$0.45 per share. At the commitment date, the date the notes were amended, the Company incurred a beneficial conversion feature of \$50,000. The amendment to the unsecured promissory notes, limited the amount of promissory notes and accrued interest that could be converted to \$225,000, effectively capping the number of common shares that could be converted to 500,000. As of the date of this filing, \$146,456 of promissory notes converted into 325,459 shares of common stock.

In September 2009, the Company entered into an agreement with University of Massachusetts General Hospital to provide financial support for the purpose of conducting an ex-vivo study of the Company's lead drug, Cytolin. This study is intended as a prelude to an in-vivo study. Costs are estimated at approximately \$550,000 of which 50%, or \$275,000, was paid to Massachusetts General Hospital

by March 2010. Subsequent to February 28, 2009 the Company agreed to provide an additional \$204,000 to Massachusetts General Hospital for the current clinical trial of Cytolin(R). This is amount in included in the cost above. This will enable the Principal Investigator to hire additional personnel in order to ensure that key data from the study will be available by December 31, 2010.

In June 2009, the Company received a request from a shareholder to convert 100,000 preferred shares into 2,356,142 restricted common shares pursuant to an Agreement dated January 2007. The common shares were to be converted at the average price per share over the last 10 days of trading prior to the conversion date which calculated to \$.62 per share. The Agreement contained a floor price of \$.30 per share, which effectively limited the maximum number of the common shares issued to an amount that was less than the Company's remaining authorized shares. These shares have not been registered with the SEC and are subject to the restrictions under Rule 144 of the Securities Act.

In February 2010, the Company negotiated a contract with Vista Biologicals Corporation to manufacture a humanized version of the company's lead product, Cytolin(R) at a cost of \$229,500, which will be paid over twelve (12) months beginning in March 2010.

22

CYTODYN, INC.
(A DEVELOPMENT STAGE COMPANY)
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
AS OF February 28, 2009
(UNAUDITED)

In September 2009, the Company's Board of Directors approved a Private Placement to sell up to 400,000 shares of the Company's Series B Convertible Preferred Stock, no par value. This offering was only available to accredited investors as defined under the 1933 Securities Act ("The Act"). The offering commenced on or about September 23, 2009 and was completed on March 29, 2010. All 400,000 shares were sold and the gross proceeds from the sale were \$2,000,000. Each share of Series B Convertible Preferred Stock will receive a 5% annual dividend and is convertible into ten (10) shares of Common Stock.

In January 2010, the Company granted 2,155,000 stock options to employees and consultants. The options have an exercise price of \$1.95 per share, expire ten years from grant, and vest between zero and three years. The approximate fair value of the options was \$3,225,000 at January 11, 2010 grant date. The fair value of these options will be recognized over the three year requisite service period.

In October 2009, the Company's Board of Directors approved a Private Placement to Sell up to 2,000,000 shares of the Company's common stock, no par value, at a price of \$.50 per share. The offering commenced on or about November 2009 and was completed on March 29, 2010. All 2,000,000 shares were sold for proceeds totaling \$1,000,000.

In April 2010, the Board issued 200,000 warrants to purchase the Company's common stock to Eware and Evolution Holdings, LLC with an exercise price of \$2.00 per share. The warrants expire September 12, 2010.

In April 2010, the Board authorized the conversion of promissory notes totaling \$9,000 into common stock at \$.45 per share.

On April 24, 2010 the Company's shareholders approved an amendment to the Company's Articles of Incorporation increasing the number of authorized shares of common stock from 25,000,000 to 100,000,000 shares effective as of April 29, 2010.

In December 2009, and May 2010, the Company repurchased 500,000 and 200,000 shares of common stock at \$.32 and \$.50 per share, respectively.

23

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion and analysis should be read in conjunction with our condensed consolidated financial statements and the related notes thereto included in this Quarterly Report on Form 10-Q. The discussion and analysis contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (Exchange Act). These forward-looking statements are based on our current expectations and entail various risks and uncertainties. Our actual results could differ materially from those projected in the forward-looking statements as a result of various factors including those set forth in "Risk Factors" of the Company's May 31, 2008 Form 10-K.

Plan of Operations

CytoDyn, Inc. discovered and is developing a class of therapeutic monoclonal antibodies to address significant unmet medical needs in the area of HIV/AIDS. CytoDyn, Inc. has sponsored a research grant to Massachusetts General Hospital in Boston, Massachusetts, to design and sponsor clinical trials in addition to conducting those trials on our lead product Cytolin(R), an immune therapy intended to treat early HIV infection. Although CytoDyn, Inc. will retain all of its intellectual property rights and will have access to the study data, the data will be owned by Massachusetts General Hospital (MGH). A chief benefit for

CytoDyn, Inc. is that the Company will benefit from MGH experience in dealing with the FDA. Moreover, the high costs and long delays associated with the FDA's oversight of clinical trials may be significantly reduced in the case of clinical trials designed and sponsored by a leading teaching hospital.

The FDA licenses medicinal products for sale in interstate commerce under a particular label. Only if they receive data supporting that label and only if some company asks them to do so. CytoDyn may or may not be the company that requests a license to market Cytolin(R) under a label. Under our current thinking we hope to enter into a strategic alliance after the next two studies under which a larger pharmaceutical marketing company will seek a license from the FDA to market Cytolin(R) and under a license from us to use our intellectual property in that manner. However there is no guarantee that we will wind up pursuing this strategy.

Projected costs to complete our research and development as a pre-requisite for

co-development and/or out-licensing.

We negotiated a contract with manufacturer Vista Biologicals Corporation to manufacture a humanized version of the company's lead product, Cytolin(R) at a cost of \$229,500, which will be paid over twelve (12) months beginning in March 2010. \$47,500 was paid by May 2010. Although a murine (mouse) version of Cytolin(R) was used for previous human experience that included some 200 patients successfully treated for up to two years, as well as an encouraging Phase I(b)/II(a) study, the Company believes that a fully-humanized version is necessary for the clinical trial that is expected to follow the current one.

The Company expects to have its proprietary, fully-humanized version of Cytolin(R) ready for bulk manufacturing in Autumn 2010 in time for a possible follow-up clinical trial.

The initial clinical trial to be conducted by Massachusetts General Hospital will cost the Company approximately \$550,000 of which \$275,000 was paid by May 18, 2010. In May 2010, the Company agreed to provide an additional \$204,000 for the current clinical trial of Cytolin(R) which is included in the cost above. This will enable the Principal Investigator to hire additional personnel in order to ensure that key data from the study will be available by December 31, 2010.

24

Subsequently, CytoDyn, Inc. may fund a follow-up clinical trial at Massachusetts General Hospital. We cannot estimate what the hospital's research grant will be until the hospital has provided those estimates.

Timing and anticipated completion dates for research and development.

We estimate that the initial clinical trial to be conducted by Massachusetts General Hospital will take one year to complete. The study enrollment began January 13, 2010. We cannot estimate when enrollment will be completed. In March 2010, the Company agreed to provide an additional \$204,000 for the current clinical trial of Cytolin(R). This will enable the Principal Investigator to hire additional personnel in order to ensure that key data from the study will be available by December 31, 2010.

There are many factors that can delay clinical trial benchmarks. However, the Company hopes to receive the results and analysis of the upcoming clinical trial during 2010.

Clinical Trials Process - Described below is the traditional drug development track. Under the Company's current business plan, much of this initial work will be sponsored and conducted by the MGH, eliminating the need for CytoDyn to deal directly with the FDA. Traditionally, the Company would enter into a strategic alliance with a larger pharmaceutical company after development has progressed to a certain point. While there can be no guarantee that this will occur in our case, if it does, then our larger partner would usually be responsible for dealing with the FDA.

Phase I

Phase I includes the initial introduction of an investigational new drug or biologic into humans. These studies are closely monitored and may be conducted in patients, but are usually conducted in a small number of healthy volunteer subjects. These studies are designed to determine the metabolic and pharmacologic actions of the investigational product in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness. During Phase I, sufficient information about the investigational product's pharmacokinetics and pharmacological effects are obtained to permit the design of well-controlled, scientifically valid, Phase II studies.

Phase II

Phase II includes the early controlled clinical studies conducted to obtain some preliminary data on the effectiveness of the drug for a particular indication or indications in patients with the disease or condition. This phase of testing also helps determine the common short-term side effects and risks associated with the drug. Phase II studies are typically well-controlled, closely monitored, and conducted in a relatively small number of patients, usually involving several hundred people. Depending upon need, a new drug may be licensed for interstate marketing after Phase II if it is a "pivotal" study.

25

Phase III

Phase III studies are expanded controlled clinical studies. They are performed after preliminary evidence suggesting effectiveness of the drug has been obtained in Phase II, and are intended to gather the additional information about effectiveness and safety that is needed to evaluate the overall benefit/risk relationship of the drug. Phase III studies also provide an adequate basis for extrapolating the results to the general population and transmitting that information in the physician labeling. Phase III studies usually include several hundred to several thousand people.

Patents

We have a License Agreement with Allen D. Allen, our president that gives us the exclusive right to develop, sell and profit from his technology worldwide. This includes issued U.S. patents 5,424,066; 5,651,970 and 6,534,057, foreign counterparts, as well as European Patents No. 94 912826.8 and 04101437.4. Hong Kong, Australian and Canadian patents have been obtained as well. The original expiration dates of the U.S. patents are 2013 to 2016. For U.S. method patents applicable to drugs approved in the U.S., the Company is entitled to a term extension of the expiration date equal to the number of years the patent was studied in clinical trials. Typically this provides another four to five years on the earliest claims. CytoDyn's counsel expects its patents to be extended until 2017 to 2020 depending upon the original date of the issued patents. We estimate the costs associated with these issued patents to be approximately \$100,000 per year. The Company expects to have its proprietary, fully-humanized version of Cytolin(R) ready for bulk manufacturing Autumn 2010 in time for the follow-up clinical trial. Based on the advice of its patent attorneys, the Company believes its fully-humanized product and a related chimeric product will be eligible for a new patent to complement and extend its existing portfolio of intellectual property, which includes patents on the use of certain antibodies to treat HIV/AIDS. We cannot estimate the costs of pursuing a new patent as of the date of this filing.

Going Concern

We will require additional funding in order to continue with research and development efforts.

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the accompanying financial statements, the Company is currently in the development stage with losses for all periods presented. As of June 23, 2010 these factors, among others, raise substantial doubt about the Company's ability to continue as a going concern.

The financial statements do not include any adjustments relating to the recoverability and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company's continuation as a going concern is dependent upon its ability to obtain additional operating capital, complete development of its medical treatments, obtain FDA approval, outsource manufacturing of the treatments, and ultimately to attain profitability. The Company intends to seek additional funding through equity offerings or licensing agreements to fund its business plan. There is no assurance that the Company will be successful in these endeavors.

26

Results of Operations

Results of Operations for the three months ended February 28, 2009 and February 29, 2008 are as follows:

For the three months ended February 28, 2009 and February 29, 2008 the Company had no activities that produced revenues from operations.

For the three months ended February 28, 2009, the Company had a net loss of \$(283,145) compared to a net loss of \$(220,107) for the corresponding period in 2008. For the three months ended February 28, 2009, the Company incurred operating expenses of \$(272,159) consisting primarily of, consulting expense, stock-based compensation, legal fees, and salaries. There was no research and development expenses for the three months ended February 28, 2009.

For the three months ended February 28, 2008, the Company had a net loss of \$(220,107). In the same period, the Company incurred operating expenses of \$(154,161) consisting primarily of stock-based compensation, legal fees and salaries.

The increase in operating expenses of \$117,998 from the three month period February 28, 2009 compared to the three months ended February 29, 2008 related primarily to an increase in consulting expenses offset by a decrease in stock compensation.

Results of Operations for the nine months ended February 28, 2009 and February 29, 2008 are as follows:

For the nine months ended February 28, 2009 and February 29, 2008 the Company had no activities that produced revenues from operations.

For the nine months ended February 28, 2009, the Company had a net loss of \$(1,499,883) compared to a net loss of \$(704,834) for the corresponding period in 2008. For the nine months ended February 28, 2009, the Company incurred operating expenses of \$(1,470,477) consisting primarily of Research and Development expenses, consulting, stock-based compensation, legal fees, and

salaries.

For the nine months ended February 29, 2008 the Company had a net loss of \$(704,834). In the same period, the Company incurred operating expenses of \$(626,047) consisting primarily of stock-based compensation, legal fees and Salaries, offset by a \$150,000 reduction in expenses related to the reversal of a litigation settlement. The increase in operating expenses of \$844,430 from the nine month period February 28, 2009 compared to the nine months ended February 29, 2008 related primarily to an increase in Research and Development expenses, salary expense, and consulting expense offset by a decrease in legal fees and stock compensation. Research and Development expense increased due to the costs associated with the development of our lead product Cytolin (R).

Liquidity and Capital Resources

As shown in the accompanying Financial Statements, for the nine months ended February 28, 2009 and February 29, 2008, and since October 28, 2003 through February 28, 2009 the Company has had net losses of \$(1,499,883) and \$(704,834) and \$(8,472,708), respectively. As of February 28, 2009, the Company has not emerged from the development stage. In view of these matters, the Company's ability to continue as a going concern is dependent upon the Company's ability to begin operations and to achieve a level of profitability. Since inception, the Company has financed its activities principally from the sale of public equity securities and proceeds from notes payable. The Company intends on financing its future development activities and its working capital needs largely from the sale of public equity securities with some additional funding from other traditional financing sources.

27

As previously mentioned, since October 28, 2003, we have financed our operations largely from the sale of common stock and proceeds from notes payable. From inception through February 28, 2009 we raised cash of approximately \$1,897,000 (net of offering costs) common stock financings and approximately \$1,534,000 through the issuance notes payable.

Since October 28, 2003 through February 28, 2009, we have incurred \$1,411,000 of research and development costs and approximately \$7,713,000 in operating expenses.

We have incurred significant net losses and negative cash flows from operations since our inception. As of February 28, 2009, we had an accumulated deficit of approximately \$(10,075,000) and a working capital deficit of approximately \$(438,000).

We anticipate that cash used in product development and operations, especially in the marketing, production and sale of our products will increase significantly in the future.

In September 2009, the Company raised \$2,000,000 through a Private Placement Offering of preferred shares. The Company amended its articles and designated 400,000 preferred shares Series B to be sold at \$5.00 share. The preferred shares are convertible into common shares at \$.50 per share or 10 shares of common for every preferred share issued. No shares have been converted as of June 23, 2010.

In April 2008, the Company's Board of Directors approved a Private Placement Memorandum to sell up to 6 million shares of common stock, no par value, a company offering. This offering was only available to accredited investors as defined under the 1933 Securities Act ("The Act"). The offering commenced on or about May 1, 2008 and ended June 15, 2009, the Company has sold 3,876,508 restricted common shares and 1,938,254 warrants for proceeds totaling approximately \$2,000,000. These securities were sold pursuant to an exemption from registration under Regulation D under The Act and will not be registered with the Securities and Exchange Commission. The warrants have an exercise price of \$1.00 per share, immediate vesting rights, and expire in April 2013.

In October 2009, the Company's Board of Directors approved a Private Placement to Sell up to 2,000,000 shares of the Company's common stock, no par value, at a price of \$.50 per share. The offering commenced on or about November 2009 and was completed on March 29, 2010. All 2,000,000 shares were sold for proceeds totaling \$1,000,000.

In September 2009 the Company entered into an agreement with Massachusetts General Hospital to provide financial support for the purpose of conducting an ex-vivo study of the Company's lead drug, Cytolin(R). This study is intended as a prelude to an in-vivo study. Costs are estimated at approximately \$550,000 of which 50%, or \$275,000, was paid to Massachusetts General Hospital by CytoDyn by September 2009.

In March 2010, the Company agreed to provide an additional \$204,000 for the current clinical trial of Cytolin(R). This will enable the Principal Investigator to hire additional personnel in order to ensure that key data from the study will be available by December 31, 2010. \$102,000 was paid in March 2010.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

Not applicable

Item 4T. Controls and Procedures

The Company's Chief Executive Officer and Chief Financial Officer have evaluated the effectiveness of the Company's disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d015(e) under the Exchange Act) as of the nine month period ending February 28, 2009 covered by this quarterly report on Form

10Q. Based upon such evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of such period, the Company's disclosure controls and procedures were not effective as required under Rules 13a015(e) and 15d-15(e) under the Exchange Act. This conclusion by the Company's Chief Executive Officer and Chief Financial Officer does not relate to reporting periods after February 28, 2009.

Changes in Control Over Financial Reporting

No change in the Company's internal control over financial reporting occurred during the quarter ended February 28, 2009, that materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting.

28

Part II

Item 1. Legal Proceedings

None

Item 2. Unregistered Sales of Equity and Use of Proceeds

In April 2008 our Board of Directors approved a Private Placement Memorandum to sell 6 million shares of common stock, no par value, through a Placement Agent, a company offering. This offering was only available to accredited investors as defined under the 1933 Securities Act ("The Act").

During the three month period ended February 28, 2009, the Company sold 239,800 restricted common shares at \$.50 per share for cash. In addition, the Company issued 219,600 shares of restricted common stock for certain consulting services at prices ranging from \$.37 to \$.50 per share. The securities were issued pursuant to an exemption from Registration under Regulation D under "The Act" and will not be registered with the Securities and Exchange Commission.

The Company used the proceeds to manufacture our primary product Cytolin(R) for use in clinical trials. The remaining amount of the proceeds will be used for Company operating expenses, patent fees and legal fees.

Item 3. Defaults Upon Senior Securities

None

Item 4. Submission of Matters to a Vote of Security Holders

None

Item 5. Other Information

None

Item 6. Exhibits and Reports on Form 8-K.

(a) Exhibits:

1. 31.1: Certification by the CEO
2. 31.2: Certification by the CFO
3. 32.1: Certification Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 - CEO
4. 32.2: Certification Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 - CFO

SIGNATURES

CYTODYN, INC.
Registrant)

DATE: June 23, 2010

BY: /s/ Allen D. Allen

Allen D. Allen
President and CEO

29

EXHIBIT 31.1
CERTIFICATIONS

I, Allen D. Allen, certify that:

1. I have reviewed this quarterly report on Form 10-Q of CytoDyn, Inc.
2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;
3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:
 - a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;
 - b) designed such internal control over financial reporting, or caused such internal control over financial reporting, to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - d) disclosed in this quarterly report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting .
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting,, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):
 - a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information ; and
 - b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

(Date) June 23, 2010

BY(Signature) /s/ Allen D. Allen
(Name and Title) Allen D. Allen
President and Chief Executive Officer

EXHIBIT 31.2
CERTIFICATIONS

I, Corinne Allen, certify that:

1. I have reviewed this quarterly report on Form 10-Q of CytoDyn, Inc.
2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;
3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:
 - a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;
 - b) designed such internal control over financial reporting, or caused such internal control over financial reporting, to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - d) disclosed in this quarterly report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting .
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting,, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):
 - a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information ; and
 - b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

(Date) June 23, 2010

BY(Signature) /s/ Corinne Allen
(Name and Title) Corinne Allen
Chief Financial Officer

EXHIBIT 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of CytoDyn, Inc. (the "Company") on Form 10-Q for the period ended February 28, 2009, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Allen D. Allen, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

- (1) The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

BY(Signature)
(Name and Title)

/s/ Allen D. Allen
Allen D. Allen
President and Chief Executive Officer

(Date)

June 23, 2010

EXHIBIT 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of CytoDyn, Inc. (the "Company") on Form 10-Q for the period ended February 28, 2009, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Corinne Allen, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

- (1) The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

BY(Signature)
(Name and Title)

/s/ Corinne Allen
Corinne Allen
Chief Financial Officer

(Date)

June 23, 2010